)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
ZyVersa Therapeutics (ZVSA) investor relations material
ZyVersa Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary19 Nov, 2025
Executive summary
Clinical-stage biopharma advancing VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, with lead indications in FSGS and cardiometabolic conditions.
Pipeline expansion potential in Alport syndrome, diabetic kidney disease, and rare kidney diseases.
No revenue generated to date; operations funded by equity and debt issuances.
Net loss of $24.3 million for the nine months ended September 30, 2025, up from $8.0 million year-over-year.
Delisted from Nasdaq in October 2025; now trading on OTCQB under symbol ZVSA.
Financial highlights
Operating expenses for the nine months ended September 30, 2025 were $24.9 million, up from $7.9 million year-over-year, driven by an $18.6 million impairment charge.
Net loss for Q3 2025 was $19.8 million, up from $2.4 million in Q3 2024, primarily due to an $18.6 million impairment charge.
Cash balance at September 30, 2025 was $0.5 million, down from $1.5 million at year-end 2024.
Research and development expenses decreased 37.6% to $1.0 million for the nine months, and 16.3% year-over-year to $0.4 million for Q3 2025.
General and administrative expenses decreased 15.1% to $5.3 million for the nine months, and 5.1% year-over-year to $1.7 million for Q3 2025.
Outlook and guidance
Cash on hand expected to fund operations on a month-to-month basis; additional capital raises and financing required for ongoing operations and pipeline development.
Plans to seek funding through equity, debt, grants, collaborations, or warrant exercises.
Anticipates continued operating losses and increased expenses as development progresses.
No assurance of profitability or successful capital raising.
Assurance of future pipeline financing
Impact of R&D impairment on drug development
R&D consultant strategy given cash constraints
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next ZyVersa Therapeutics earnings date
Q4 202526 Mar, 2026
Next ZyVersa Therapeutics earnings date
Q4 202526 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company dedicated to developing innovative drugs for renal and inflammatory diseases with significant unmet medical needs. The company leverages advanced proprietary technologies to create first-in-class therapeutics. Its key product candidates include the Cholesterol Efflux Mediator VAR 200, which is being developed to remove excess cholesterol from the kidneys' filtration system to prevent damage and reduce proteinuria, potentially treating conditions like diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and Alport syndrome. Another major candidate is the Inflammasome ASC Inhibitor IC 100, a monoclonal antibody designed to inhibit inflammation by targeting the ASC protein, which is implicated in a variety of inflammatory conditions, including neuroinflammatory diseases like Parkinson’s and Alzheimer’s, as well as metabolic complications related to obesity. The company is headquartered in Weston, Florida, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage